M
Michael S. Diamond
Researcher at Washington University in St. Louis
Publications - 538
Citations - 64976
Michael S. Diamond is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Antibody & Virus. The author has an hindex of 124, co-authored 453 publications receiving 49245 citations. Previous affiliations of Michael S. Diamond include Harvard University & University of Washington.
Papers
More filters
Journal ArticleDOI
Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity
Kai Hildner,Brian T. Edelson,Whitney E. Purtha,Mark S Diamond,Hirokazu Matsushita,Masako Kohyama,Boris Calderon,Barbara U. Schraml,Emil R. Unanue,Michael S. Diamond,Robert D. Schreiber,Theresa L. Murphy,Kenneth M. Murphy +12 more
TL;DR: An important role is suggested for CD8α+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection in Batf3–/– mice.
Journal ArticleDOI
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Dora Pinto,Young-Jun Park,Martina Beltramello,Alexandra C. Walls,M. Alejandra Tortorici,M. Alejandra Tortorici,Siro Bianchi,Stefano Jaconi,Katja Culap,Fabrizia Zatta,Anna De Marco,Alessia Peter,Barbara Guarino,Roberto Spreafico,Elisabetta Cameroni,James Brett Case,Rita E. Chen,Colin Havenar-Daughton,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Antonio Lanzavecchia,Michael S. Diamond,Katja Fink,David Veesler,Davide Corti +25 more
TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Journal ArticleDOI
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus
Leonid Gitlin,Winfried Barchet,Susan Gilfillan,Marina Cella,Bruce Beutler,Richard A. Flavell,Michael S. Diamond,Marco Colonna +7 more
TL;DR: It is shown that mda-5 is the dominant receptor mediating type I IFN secretion in response to polyI:C in vitro and in vivo, and selectively impaired antiviral response to encephalomyocarditis picornavirus is exhibited, indicating functional specialization of mda -5 in vivo.
Journal ArticleDOI
ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18).
Michael S. Diamond,Donald E. Staunton,A R de Fougerolles,Steven A. Stacker,Julio Garcia-Aguilar,Margaret L. Hibbs,Timothy A. Springer +6 more
TL;DR: It is concluded that ICAM-1 is a counter receptor for Mac-1 and that this receptor pair is responsible, in part, for the adhesion between stimulated neutrophils and stimulated endothelial cells.
Journal ArticleDOI
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Seth J. Zost,Pavlo Gilchuk,James Brett Case,Elad Binshtein,Rita E. Chen,Joseph P. Nkolola,Alexandra Schäfer,Joseph X. Reidy,Andrew Trivette,Rachel S. Nargi,Rachel E. Sutton,Naveenchandra Suryadevara,David R. Martinez,Lauren E. Williamson,Elaine C. Chen,Taylor Jones,Samuel Day,Luke Myers,Ahmed O. Hassan,Natasha M. Kafai,Emma S. Winkler,Julie M. Fox,Swathi Shrihari,Benjamin K. Mueller,Jens Meiler,Jens Meiler,Abishek Chandrashekar,Noe B. Mercado,James J. Steinhardt,Kuishu Ren,Yueh-Ming Loo,Nicole L. Kallewaard,Broc T. McCune,Shamus P. Keeler,Michael J. Holtzman,Dan H. Barouch,Lisa E. Gralinski,Ralph S. Baric,Larissa B. Thackray,Michael S. Diamond,Robert H. Carnahan,James E. Crowe +41 more
TL;DR: An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.